Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine

Abstract

Introduction: Methadone and buprenorphine are maintenance replacement therapies for opioid dependence; they are also used for pain management. Methadone and buprenorphine (to a lesser extent) have seen sharp increases in mortality associated with their use. They have distinct routes of metabolism (mostly cytochrome P450 dependent), and distinct pharmacologic activity of metabolites. As such, metabolism may play a role in differences in their toxicity.

Areas covered: This article reviews peer-reviewed literature obtained from PubMed searches and literature referenced within. The review considers first an overview of drug use and mortality over the past decade. It then provides extensive detail on the in vitro and in vivo human metabolism of methadone and buprenorphine. Using both human and experimental animal studies it then presents the pharmacodynamic activity of parent drug and metabolites at the mu-opioid receptor, as P-glycoprotein substrates and plasma/brain concentration ratios, and activity at the hERG K⁺ channel. Lessons learned from drug interaction studies in humans are then examined in an attempt to bring together the combined information.

Expert opinion: The use and misuse of these drugs contributes to the epidemic in opioid-associated mortalities. A better understanding of metabolism-, transport- and co-medication-induced changes will contribute to their safer use.

Keywords::

• buprenorphine
• cytochrome P450
• drug interaction
• drug metabolism
• human ether-a-go-go-related gene K⁺ channels
• methadone
• opioid receptor agonists
• opioid replacement therapy
• P-glycoprotein
• prolonged QT interval
• respiratory depression
• UDP-glucuronosyltransferase

Acknowledgement

The author would like to thank D Rollins, S Walsh and the reviewers for their useful comments on the manuscript.

Notes

This box summarizes key points contained in the article.